{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-019097","form_type":"8-K","ticker":"SHPH","cik":"0001757499","company_name":"Shuttle Pharmaceuticals Holdings, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.916596+00:00","generated_at":"2026-06-02T01:03:11.592914+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Shuttle Pharma Q1 update: FDA clears Phase 2 glioblastoma trial; cash $4.2M","bullets":["FDA approved Phase 2 trial of Ropidoxuridine for glioblastoma; central IRB approved; first patient dosing expected Q2 2024.","Cash and marketable securities at March 31, 2024 totaled approx. $4.2 million.","Formed new wholly owned subsidiary Shuttle Diagnostics to develop predictive biomarker tests for prostate cancer.","Obtained exclusive licenses from Georgetown University for predictive biomarker program and PSMA-B IP for metastatic prostate cancer.","Finalizing site enrollment at up to six institutions for Phase 2 trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-019097","json":"https://secwatch.observer/filing/0001493152-24-019097.json","markdown":"https://secwatch.observer/filing/0001493152-24-019097.md","text":"https://secwatch.observer/filing/0001493152-24-019097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1757499/000149315224019097/0001493152-24-019097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1757499/000149315224019097/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:03:11.592914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c884802dd9d9d36fe643e9d5b5c62c6b5330418d","claim":"Shuttle Pharmaceuticals Holdings, Inc. reported preliminary financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 14, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), issued a press release providing a corporate update in connection with the filing of our Quarterly Report on Form 10-Q for the period ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315224019097/0001493152-24-019097-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}